Clin Gastroenterology H: Patients with rheumatoid arthritis who received immunosuppressive treatment had a low risk of serum conversion reversal.

In patients cured of hepatitis B virus (HBV) infection, treatment for related diseases in patients with rheumatoid arthritis (RA) can lead to the re-emergence of hepatitis B surface antigens (HBsAg), known as reverse serum transformation.
study looked at the clinical characteristics and serum reversals of patients treated with immunosuppressants or biotherapy RA.
researchers collected data on antibody levels of HBc core antigens and HBsAg from 1,494 RA patients (925 cases of cured HBV infection) who were treated at Rongmin General Hospital in Taipei from January 2007 to December 2017.
This study identified 17 patients with HBsAg negative before RA treatment, and 13 patients with glucoticoid therapy and/or biotherapy (Adamo monoantigen, n s 2; inasip, n s1; lyxi monoanti, n serotonin, n serotonin) or serum reversal (HBs reproduced Ag) negative.
time from immunosuppressive therapy to serum reversal was 120 months, while the time from biological therapy to serum reversal was 66 months.
reverse serum conversion, 8 people (47.1%) tested positive for HBe antigen.
9 cases (52.9%) did not show a re-elevation of alanine transaminase.
, three cases (17.6 per cent) had liver failure.
this study confirms that in patients who recover from HBV infection and are treated with RA immunosuppressants, the risk of serum conversion reversal is low, but can last up to 10 years.
once immunosuppressive treatment for RA begins, HBsAg and HBV DNA levels should be monitored in RA patients who have previously been treated for HBV infection.
.